AIM
GALT icon

Acrospire Investment Management’s Galectin Therapeutics GALT Stock Holding History

Acrospire Investment Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6,575
Closed -$16K – 560
2017
Q2 		$16K Buy
+6,575
New +$17.5K 0.02% 1638
2016
Q4 		– Sell
-5,500
Closed -$6K – 2281
2016
Q3 		$6K Buy
+5,500
New +$9.78K ﹤0.01% 1793

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acrospire Investment Management's GALT Position: Q3 2017 in Review

Acrospire Investment Management sold out of Galectin Therapeutics (GALT) in Q3 2017, closing a stake of 6,575 shares — an estimated $16K sold.

Acrospire Investment Management first reported a position in GALT in Q3 2016 and held it in 2 quarters. The position peaked at $16K in Q2 2017. 49 funds tracked by Wall St. Rank hold GALT as of Q3 2017.

  • Acrospire Investment Management reported no remaining Galectin Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 6,575 Galectin Therapeutics shares in Q3 2017, an estimated $16K.
  • Acrospire Investment Management first reported a position in Galectin Therapeutics in Q3 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Galectin Therapeutics position peaked at $16K in Q2 2017.
  • 49 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.